
<!doctype html>
<html lang="en" class="no-js">
  <head>
    
      <meta charset="utf-8">
      <meta name="viewport" content="width=device-width,initial-scale=1">
      
      
        <meta name="author" content="YW Chen">
      
      
        <link rel="canonical" href="https://didiowen.github.io/notes-not-scandal/archive/2024/page/3/">
      
      
        <link rel="prev" href="../../../../category/writing/">
      
      
        <link rel="next" href="../../../2023/">
      
      
      <link rel="icon" href="../../../../assets/images/favicon.png">
      <meta name="generator" content="mkdocs-1.6.1, mkdocs-material-9.5.33">
    
    
      
        <title>2024 - Notes Not Scandal</title>
      
    
    
      <link rel="stylesheet" href="../../../../assets/stylesheets/main.3cba04c6.min.css">
      
        
        <link rel="stylesheet" href="../../../../assets/stylesheets/palette.06af60db.min.css">
      
      


    
    
      
    
    
      
        
        
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
        <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:300,300i,400,400i,700,700i%7CRoboto+Mono:400,400i,700,700i&display=fallback">
        <style>:root{--md-text-font:"Roboto";--md-code-font:"Roboto Mono"}</style>
      
    
    
      <link rel="stylesheet" href="../../../../css/timeago.css">
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/6.0.0-beta3/css/all.min.css">
    
    <script>__md_scope=new URL("../../../..",location),__md_hash=e=>[...e].reduce((e,_)=>(e<<5)-e+_.charCodeAt(0),0),__md_get=(e,_=localStorage,t=__md_scope)=>JSON.parse(_.getItem(t.pathname+"."+e)),__md_set=(e,_,t=localStorage,a=__md_scope)=>{try{t.setItem(a.pathname+"."+e,JSON.stringify(_))}catch(e){}}</script>
    
      

    
    
    
  </head>
  
  
    
    
      
    
    
    
    
    <body dir="ltr" data-md-color-scheme="default" data-md-color-primary="pink" data-md-color-accent="indigo">
  
    
    <input class="md-toggle" data-md-toggle="drawer" type="checkbox" id="__drawer" autocomplete="off">
    <input class="md-toggle" data-md-toggle="search" type="checkbox" id="__search" autocomplete="off">
    <label class="md-overlay" for="__drawer"></label>
    <div data-md-component="skip">
      
        
        <a href="#2024" class="md-skip">
          Skip to content
        </a>
      
    </div>
    <div data-md-component="announce">
      
    </div>
    
    
      

  

<header class="md-header md-header--shadow" data-md-component="header">
  <nav class="md-header__inner md-grid" aria-label="Header">
    <a href="../../../.." title="Notes Not Scandal" class="md-header__button md-logo" aria-label="Notes Not Scandal" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54Z"/></svg>

    </a>
    <label class="md-header__button md-icon" for="__drawer">
      
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M3 6h18v2H3V6m0 5h18v2H3v-2m0 5h18v2H3v-2Z"/></svg>
    </label>
    <div class="md-header__title" data-md-component="header-title">
      <div class="md-header__ellipsis">
        <div class="md-header__topic">
          <span class="md-ellipsis">
            Notes Not Scandal
          </span>
        </div>
        <div class="md-header__topic" data-md-component="header-topic">
          <span class="md-ellipsis">
            
              2024
            
          </span>
        </div>
      </div>
    </div>
    
      
        <form class="md-header__option" data-md-component="palette">
  
    
    
    
    <input class="md-option" data-md-color-media="(prefers-color-scheme: light)" data-md-color-scheme="default" data-md-color-primary="pink" data-md-color-accent="indigo"  aria-label="Switch to dark mode"  type="radio" name="__palette" id="__palette_0">
    
      <label class="md-header__button md-icon" title="Switch to dark mode" for="__palette_1" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 6H7c-3.31 0-6 2.69-6 6s2.69 6 6 6h10c3.31 0 6-2.69 6-6s-2.69-6-6-6zm0 10H7c-2.21 0-4-1.79-4-4s1.79-4 4-4h10c2.21 0 4 1.79 4 4s-1.79 4-4 4zM7 9c-1.66 0-3 1.34-3 3s1.34 3 3 3 3-1.34 3-3-1.34-3-3-3z"/></svg>
      </label>
    
  
    
    
    
    <input class="md-option" data-md-color-media="(prefers-color-scheme: dark)" data-md-color-scheme="slate" data-md-color-primary="pink" data-md-color-accent="blue"  aria-label="Switch to light mode"  type="radio" name="__palette" id="__palette_1">
    
      <label class="md-header__button md-icon" title="Switch to light mode" for="__palette_0" hidden>
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M17 7H7a5 5 0 0 0-5 5 5 5 0 0 0 5 5h10a5 5 0 0 0 5-5 5 5 0 0 0-5-5m0 8a3 3 0 0 1-3-3 3 3 0 0 1 3-3 3 3 0 0 1 3 3 3 3 0 0 1-3 3Z"/></svg>
      </label>
    
  
</form>
      
    
    
      <script>var media,input,key,value,palette=__md_get("__palette");if(palette&&palette.color){"(prefers-color-scheme)"===palette.color.media&&(media=matchMedia("(prefers-color-scheme: light)"),input=document.querySelector(media.matches?"[data-md-color-media='(prefers-color-scheme: light)']":"[data-md-color-media='(prefers-color-scheme: dark)']"),palette.color.media=input.getAttribute("data-md-color-media"),palette.color.scheme=input.getAttribute("data-md-color-scheme"),palette.color.primary=input.getAttribute("data-md-color-primary"),palette.color.accent=input.getAttribute("data-md-color-accent"));for([key,value]of Object.entries(palette.color))document.body.setAttribute("data-md-color-"+key,value)}</script>
    
    
    
      <label class="md-header__button md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
      </label>
      <div class="md-search" data-md-component="search" role="dialog">
  <label class="md-search__overlay" for="__search"></label>
  <div class="md-search__inner" role="search">
    <form class="md-search__form" name="search">
      <input type="text" class="md-search__input" name="query" aria-label="Search" placeholder="Search" autocapitalize="off" autocorrect="off" autocomplete="off" spellcheck="false" data-md-component="search-query" required>
      <label class="md-search__icon md-icon" for="__search">
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M9.5 3A6.5 6.5 0 0 1 16 9.5c0 1.61-.59 3.09-1.56 4.23l.27.27h.79l5 5-1.5 1.5-5-5v-.79l-.27-.27A6.516 6.516 0 0 1 9.5 16 6.5 6.5 0 0 1 3 9.5 6.5 6.5 0 0 1 9.5 3m0 2C7 5 5 7 5 9.5S7 14 9.5 14 14 12 14 9.5 12 5 9.5 5Z"/></svg>
        
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
      </label>
      <nav class="md-search__options" aria-label="Search">
        
        <button type="reset" class="md-search__icon md-icon" title="Clear" aria-label="Clear" tabindex="-1">
          
          <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M19 6.41 17.59 5 12 10.59 6.41 5 5 6.41 10.59 12 5 17.59 6.41 19 12 13.41 17.59 19 19 17.59 13.41 12 19 6.41Z"/></svg>
        </button>
      </nav>
      
    </form>
    <div class="md-search__output">
      <div class="md-search__scrollwrap" tabindex="0" data-md-scrollfix>
        <div class="md-search-result" data-md-component="search-result">
          <div class="md-search-result__meta">
            Initializing search
          </div>
          <ol class="md-search-result__list" role="presentation"></ol>
        </div>
      </div>
    </div>
  </div>
</div>
    
    
  </nav>
  
</header>
    
    <div class="md-container" data-md-component="container">
      
      
        
          
        
      
      <main class="md-main" data-md-component="main">
        <div class="md-main__inner md-grid">
          
            
              
              <div class="md-sidebar md-sidebar--primary" data-md-component="sidebar" data-md-type="navigation" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    



<nav class="md-nav md-nav--primary" aria-label="Navigation" data-md-level="0">
  <label class="md-nav__title" for="__drawer">
    <a href="../../../.." title="Notes Not Scandal" class="md-nav__button md-logo" aria-label="Notes Not Scandal" data-md-component="logo">
      
  
  <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M12 8a3 3 0 0 0 3-3 3 3 0 0 0-3-3 3 3 0 0 0-3 3 3 3 0 0 0 3 3m0 3.54C9.64 9.35 6.5 8 3 8v11c3.5 0 6.64 1.35 9 3.54 2.36-2.19 5.5-3.54 9-3.54V8c-3.5 0-6.64 1.35-9 3.54Z"/></svg>

    </a>
    Notes Not Scandal
  </label>
  
  <ul class="md-nav__list" data-md-scrollfix>
    
      
      
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../.." class="md-nav__link">
        
  
  <span class="md-ellipsis">
    Home
  </span>
  

      </a>
    </li>
  

    
      
      
  
  
    
  
  
  
    
    
    
    
    <li class="md-nav__item md-nav__item--active md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_2" checked>
        
          
          <label class="md-nav__link" for="__nav_2" id="__nav_2_label" tabindex="0">
            
  
  <span class="md-ellipsis">
    Archive
  </span>
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_2_label" aria-expanded="true">
          <label class="md-nav__title" for="__nav_2">
            <span class="md-nav__icon md-icon"></span>
            Archive
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
    
      
    
  
  
    <li class="md-nav__item">
      
      <input class="md-nav__toggle md-toggle" type="checkbox" id="__toc">
      
      
        
      
      
        <label class="md-nav__link md-nav__link--active" for="__toc">
          
  
  <span class="md-ellipsis">
    2024
  </span>
  

          <span class="md-nav__icon md-icon"></span>
        </label>
      
      <a href="../../" class="md-nav__link md-nav__link--active">
        
  
  <span class="md-ellipsis">
    2024
  </span>
  

      </a>
      
        

  

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#antibiotics" class="md-nav__link">
    <span class="md-ellipsis">
      Antibiotics
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#cns-infection" class="md-nav__link">
    <span class="md-ellipsis">
      CNS Infection
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#coronavirus-disease-2019-covid-19-sars-cov-2-infection" class="md-nav__link">
    <span class="md-ellipsis">
      CORONAVIRUS DISEASE 2019 (COVID-19) / SARS-COV-2 INFECTION
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
      
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../2023/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    2023
  </span>
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
      
      
  
  
  
  
    
    
    
    
    <li class="md-nav__item md-nav__item--nested">
      
        
        
        <input class="md-nav__toggle md-toggle " type="checkbox" id="__nav_3" >
        
          
          <label class="md-nav__link" for="__nav_3" id="__nav_3_label" tabindex="0">
            
  
  <span class="md-ellipsis">
    Categories
  </span>
  

            <span class="md-nav__icon md-icon"></span>
          </label>
        
        <nav class="md-nav" data-md-level="1" aria-labelledby="__nav_3_label" aria-expanded="false">
          <label class="md-nav__title" for="__nav_3">
            <span class="md-nav__icon md-icon"></span>
            Categories
          </label>
          <ul class="md-nav__list" data-md-scrollfix>
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/abx/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    abx
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/hiv/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    hiv
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/medicine/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    medicine
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/reading/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    reading
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/taiwanese/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    taiwanese
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/tb/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    tb
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/travelling/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    travelling
  </span>
  

      </a>
    </li>
  

              
            
              
                
  
  
  
    
  
  
    <li class="md-nav__item">
      <a href="../../../../category/writing/" class="md-nav__link">
        
  
  <span class="md-ellipsis">
    writing
  </span>
  

      </a>
    </li>
  

              
            
          </ul>
        </nav>
      
    </li>
  

    
  </ul>
</nav>
                  </div>
                </div>
              </div>
            
            
              
              <div class="md-sidebar md-sidebar--secondary" data-md-component="sidebar" data-md-type="toc" >
                <div class="md-sidebar__scrollwrap">
                  <div class="md-sidebar__inner">
                    

  

<nav class="md-nav md-nav--secondary" aria-label="Table of contents">
  
  
  
    
  
  
    <label class="md-nav__title" for="__toc">
      <span class="md-nav__icon md-icon"></span>
      Table of contents
    </label>
    <ul class="md-nav__list" data-md-component="toc" data-md-scrollfix>
      
        <li class="md-nav__item">
  <a href="#antibiotics" class="md-nav__link">
    <span class="md-ellipsis">
      Antibiotics
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#cns-infection" class="md-nav__link">
    <span class="md-ellipsis">
      CNS Infection
    </span>
  </a>
  
</li>
      
        <li class="md-nav__item">
  <a href="#coronavirus-disease-2019-covid-19-sars-cov-2-infection" class="md-nav__link">
    <span class="md-ellipsis">
      CORONAVIRUS DISEASE 2019 (COVID-19) / SARS-COV-2 INFECTION
    </span>
  </a>
  
</li>
      
    </ul>
  
</nav>
                  </div>
                </div>
              </div>
            
          
          
  <div class="md-content" data-md-component="content">
    <div class="md-content__inner">
      <header class="md-typeset">
        <h1 id="2024">2024<a class="headerlink" href="#2024" title="Permanent link">&para;</a></h1>
      </header>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-09 00:00:00">August 9, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="../../../../category/medicine/" class="md-meta__link">medicine</a>, 
              <a href="../../../../category/abx/" class="md-meta__link">abx</a></li>
        
        
          
          <li class="md-meta__item">
            
              8 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="antibiotics"><a class="toclink" href="../../../../medicine/antibiotics/">Antibiotics</a></h2>
<h3 id="_1"><a class="toclink" href="../../../../medicine/antibiotics/#_1">作用機制</a></h3>
<p><img alt="mechanism" src="../../assets/images/d5cd1072950af118968f9283c66a7d7c_MD5.jpeg" />  </p>
<hr />
<table>
<thead>
<tr>
<th>ANTIBACTERIAL AGENT(S)</th>
<th>MAJOR TARGET</th>
<th>MECHANISM(S) OF ACTION</th>
<th>MECHANISM(S) OF RESISTANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-Lactams (penicillins, cephalosporins, monobactams, carbapenems)</td>
<td>Cell-wall synthesis</td>
<td>Bind cell-wall cross-linking enzymes (PBPs, <strong>transpeptidases</strong>)</td>
<td>1. Drug inactivation by β-lactamases<br>    <br>2. Altered PBP targets<br>    <br>3. Reduced diffusion through porin channels<br>    <br>4. Altered iron uptake proteins (cefiderocol)</td>
</tr>
<tr>
<td>Glycopeptides and lipoglycopeptides (vancomycin, teicoplanin, telavancin, dalbavancin, oritavancin)</td>
<td>Cell-wall synthesis</td>
<td>Block cell wall glycosyltransferases by binding D-Ala-D-Ala stem-peptide terminus<br><br>Teicoplanin, telavancin, dalbavancin, and oritavancin: affect membrane function</td>
<td>1. Altered D-Ala-D-Ala target (D-Ala-D-Lac)<br>    <br>2. Increased D-Ala-D-Ala target binding at sites distant from cell wall synthesis enzymes</td>
</tr>
<tr>
<td>Bacitracin</td>
<td>Cell-wall synthesis</td>
<td>Blocks lipid carrier of cell wall precursors</td>
<td>Active drug efflux</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>Cell-wall synthesis</td>
<td>Blocks linkage of stem peptide to NAG by enoyltransferase</td>
<td>1. Target enzyme overexpression<br>    <br>2. Drug-modifying enzymes</td>
</tr>
<tr>
<td>Aminoglycosides (gentamicin, tobramycin, amikacin, plazomicin)</td>
<td>Protein synthesis</td>
<td>Bind 30S ribosomal subunit<br><br>Block translocation of peptide chain<br><br>Cause misreading of mRNA</td>
<td>1. Drug-modifying enzymes<br>    <br>2. Methylation at ribosome binding site<br>    <br>3. Decreased permeation to target due to active efflux</td>
</tr>
<tr>
<td>Tetracyclines (tetracycline, doxycycline, minocycline)</td>
<td>Protein synthesis</td>
<td>Bind 30S ribosomal subunit<br><br>Inhibit peptide elongation</td>
<td>1. Active drug efflux<br>    <br>2. Ribosomal protection proteins</td>
</tr>
<tr>
<td>Tigecycline, eravacyclin, omadacycline</td>
<td>Protein synthesis</td>
<td>Same as tetracyclines</td>
<td>Active drug efflux (pumps different from those affecting tetracyclines)</td>
</tr>
<tr>
<td>Macrolides (erythromycin, clarithromycin, azithromycin) and the ketolide telithromycin</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Block peptide chain exit</td>
<td>1. Methylation at ribosome binding site<br>    <br>2. Active drug efflux</td>
</tr>
<tr>
<td>Lincosamides (clindamycin)</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Block peptide bond formation</td>
<td>Methylation at ribosome binding site</td>
</tr>
<tr>
<td>Streptogramins (quinupristin, dalfopristin)</td>
<td>Protein synthesis</td>
<td>Same as macrolides</td>
<td>1. Same as macrolides<br>    <br>2. Drug-modifying enzymes</td>
</tr>
<tr>
<td>Chloramphenicol</td>
<td>Protein synthesis</td>
<td>Binds 50S ribosomal subunit<br><br>Blocks aminoacyl tRNA positioning</td>
<td>Drug-modifying enzymes</td>
</tr>
<tr>
<td>Oxazolidinones (linezolid, tedizolid)</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Inhibit initiation of peptide synthesis</td>
<td>1. Altered rRNA binding site<br>    <br>2. Methylation of ribosome binding site</td>
</tr>
<tr>
<td>Pleuromutilins (lefamulin)</td>
<td>Protein synthesis</td>
<td>Bind 50S ribosomal subunit<br><br>Blocks peptidyl transferase center</td>
<td>1. Altered L3 and L4 protein binding site<br>    <br>2. Methylation of ribosome binding site</td>
</tr>
<tr>
<td>Mupirocin</td>
<td>Protein synthesis</td>
<td>Blocks isoleucyl tRNA synthetase</td>
<td>1. Acquired resistant tRNA synthetase (drug bypass)<br>    <br>2. Altered native tRNA synthetase target</td>
</tr>
<tr>
<td>Sulfonamides (sulfadiazine, sulfisoxazole, and sulfamethoxazole)</td>
<td>Folate synthesis</td>
<td>Inhibit dihydropteroate synthetase</td>
<td>Acquired resistant dihydropteroate synthetase (drug bypass)</td>
</tr>
<tr>
<td>Trimethoprim</td>
<td>Folate synthesis</td>
<td>Inhibits dihydrofolate reductase</td>
<td>Acquired resistant dihydrofolate reductase (drug bypass)</td>
</tr>
<tr>
<td>Quinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin, delafloxacin)</td>
<td>DNA synthesis</td>
<td>Inhibit DNA gyrase and DNA topoisomerase IV<br><br>Enzyme–DNA–drug complex: blocks DNA replication apparatus</td>
<td>1. Altered target(s)<br>    <br>2. Active efflux<br>    <br>3. Protection of target from drug<br>    <br>4. Drug-modifying enzyme (ciprofloxacin)</td>
</tr>
<tr>
<td>Rifamycins (rifampin, rifabutin, rifapentine)</td>
<td>RNA synthesis</td>
<td>Inhibit RNA polymerase</td>
<td>Altered target</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>Nucleic acid synthesis</td>
<td>Reduces reactive drug derivatives that damage DNA</td>
<td>Altered drug-activating enzymes</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Nucleic acid synthesis</td>
<td>Reduces reactive drug derivatives that damage DNA</td>
<td>1. Altered drug-activating enzyme<br>    <br>2. Acquired detoxifying enzymes<br>    <br>3. Active efflux</td>
</tr>
<tr>
<td>Polymyxins (polymyxin B and polymyxin E [colistin])</td>
<td>Cell membrane</td>
<td>Bind LPS and disrupt both outer and cytoplasmic membranes</td>
<td>Altered cell-membrane charge with reduced drug binding</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>Cell membrane</td>
<td>Produces membrane channel and membrane leakage</td>
<td>Altered cell-membrane charge with reduced drug binding</td>
</tr>
</tbody>
</table>
<h4 id="_2"><a class="toclink" href="../../../../medicine/antibiotics/#_2">抗藥性機轉</a></h4>
<p><img alt="resistance_zh" src="../../assets/images/be7c385cf6d7376b54c4de4794df94d7_MD5.jpeg" /><br />
<img alt="resistance_en" src="../../assets/images/64e57133364b2f9716df1ac514b4d418_MD5.jpeg" />  </p>
<h4 id="_3"><a class="toclink" href="../../../../medicine/antibiotics/#_3">藥物動力學</a></h4>
<ul>
<li>藥物動力學：描述藥物在體內的分布情況  </li>
<li>藥效動力學：描述藥物作用於病原體的決定因素，並與藥物動力學因素相關  </li>
</ul>
<h5 id="_4"><a class="toclink" href="../../../../medicine/antibiotics/#_4">濃度依賴型抗生素</a></h5>
<p>這類抗生素多為抑制細菌蛋白質或核酸合成的抗生素，如aminoglycosides、fluoroquinolones，因其殺菌作用與血中濃度呈正比，為達最大之殺菌作用，建議抗生素之Cmax須高於MIC 4倍以上，且因其有抗生素後效應 (Post-antibiotic effect,PAE) 的特性，即便血中藥物濃度在給藥間隔期間內低於MIC，仍可維持一定的抗菌作用。因此採高劑量、延長給藥間隔的方式投予是比較理想的方式，once-daily<br />
aminoglycoside的給藥模式即以此理念所發展。  </p>
<h5 id="_5"><a class="toclink" href="../../../../medicine/antibiotics/#_5">時間依賴型抗生素</a></h5>
<p>這類抗生素多為beta-lactams類，如penicillin、cephalosporins。對penicillin和cephalosporins而言，血中藥物濃度&gt;MIC的時間越長越能滲透體內組織，建議治療期間的血中濃度有50%以上的時間高於MIC，以達療效最大化、抗生素耐藥性最小化的目標。此類藥品以連續輸注或延長輸注時間的方式給藥，除了可穩定抗生素血中濃<br />
度的變化、不增加重症患者AKI的發生率外，對整體的醫療照護支出費用也可顯著降低。  </p>
<h5 id="_6"><a class="toclink" href="../../../../medicine/antibiotics/#_6">曲線下面積/最低抑菌濃度相關</a></h5>
<p>如vancomycin，建議血中藥物濃度之曲線下面積 (AUC) 與MIC比值達到400-600<br />
mg × h/L的目標（假設MIC為1），可確保抗生素療效與安全性。  </p>
<h4 id="penetrationtissue-concentration"><a class="toclink" href="../../../../medicine/antibiotics/#penetrationtissue-concentration">Penetration/Tissue concentration</a></h4>
<ul>
<li>過BBB: penicillin, ampicillin, oxacillin, 3rd-4th cephalosporins, moxifloxacin, vancomycin, chloramphenicol, rifampin, imipenem, meropenem, trimethoprim-sulfamethoxazole  </li>
<li>Prostatitis/epididymo-orchitis: ceftriaxone, doxycycline, fluoroquinolones, trimethoprim-sulfamethoxazole  </li>
<li>Endophthalmitis: 3rd cepha, vancomycin  </li>
</ul>
<h3 id="_7"><a class="toclink" href="../../../../medicine/antibiotics/#_7">本院有的抗生素</a></h3>
<h4 id="cephalosporins"><a class="toclink" href="../../../../medicine/antibiotics/#cephalosporins">Cephalosporins</a></h4>
<p>第一代：Cefazolin, cephalexin (PO)<br />
第二代：Cefuroxime (IV, PO)<br />
第三代：Ceftriaxone, ceftazidime, cefoperazone/sulbactam, ceftazidime/avibactam, cefixime (PO)<br />
第四代：Cefepime<br />
第五代：Ceftaroline  </p>
<h4 id="penicillins"><a class="toclink" href="../../../../medicine/antibiotics/#penicillins">Penicillins</a></h4>
<p>Penicillin G, penicillin benzathine (IM)<br />
Oxacillin, dicloxacillin (PO)<br />
Ampicillin, ampicillin/sulbactam<br />
Amoxicillin, amoxicillin/clavulanic acid (PO)<br />
Piperacillin, piperacillin/tazobactam  </p>
<h4 id="carbapenems"><a class="toclink" href="../../../../medicine/antibiotics/#carbapenems">Carbapenems</a></h4>
<p>Ertapenem, imipenem/cilastatin, meropenem  </p>
<h4 id="aminoglycosides"><a class="toclink" href="../../../../medicine/antibiotics/#aminoglycosides">Aminoglycosides</a></h4>
<p>Gentamicin, amikacin  </p>
<h4 id="fluoroquinolones"><a class="toclink" href="../../../../medicine/antibiotics/#fluoroquinolones">Fluoroquinolones</a></h4>
<p>Moxifloxacin, ciprofloxacin, levofloxacin (IV, PO)  </p>
<h4 id="tetracyclines"><a class="toclink" href="../../../../medicine/antibiotics/#tetracyclines">Tetracyclines</a></h4>
<p>Tetracycline (PO), doxycycline (PO), tigecycline, minocycline  </p>
<h4 id="macrolides"><a class="toclink" href="../../../../medicine/antibiotics/#macrolides">Macrolides</a></h4>
<p>Azithromycin (PO), clarithromycin (PO), erythromycin  </p>
<h4 id="glycopeptides-lipoglycopeptides-daptomycin-oxazolidinones"><a class="toclink" href="../../../../medicine/antibiotics/#glycopeptides-lipoglycopeptides-daptomycin-oxazolidinones">Glycopeptides, lipoglycopeptides, daptomycin, oxazolidinones</a></h4>
<p>Vancomycin, teicoplanin, daptomycin, linezolid (IV, PO)  </p>
<h4 id="other-anti-bacterials"><a class="toclink" href="../../../../medicine/antibiotics/#other-anti-bacterials">Other anti-bacterials</a></h4>
<p>Clindamycin (PO)<br />
Fosfomycin (IV, PO)<br />
Trimethoprim-sulfamethoxazole (PO)<br />
Colistin<br />
Metronidazole (IV, PO)<br />
Rifampin, isoniazid, ethambutol, pyrazinamide (PO)  </p>
<h4 id="anti-fungals"><a class="toclink" href="../../../../medicine/antibiotics/#anti-fungals">Anti-fungals</a></h4>
<p>Fluconazole (IV, PO): 對<em>Aspergillus spp., Candida krusei</em>無效; <em>Candida glabrata, Candida tropicalis</em>也可能沒效<br />
Voriconazole (IV, PO)<br />
Isavuconazole<br />
Anidulafungin<br />
Amphotericin B liposome  </p>
<h3 id="_8"><a class="toclink" href="../../../../medicine/antibiotics/#_8">抗菌範圍</a></h3>
<p><img alt="../assets/images/7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg|7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg" src="../../assets/images/7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg|7e8b9088434a32c9d865e91bb156fd55_MD5.jpeg" /><br />
<a href="http://charliekuo.com/?p=3114">Source</a>  </p>
<h4 id="anfi-fungals"><a class="toclink" href="../../../../medicine/antibiotics/#anfi-fungals">Anfi-fungals</a></h4>
<table>
<thead>
<tr>
<th>Organism</th>
<th>AmB</th>
<th>Fluconazole</th>
<th>Vori</th>
<th>Isavu</th>
<th>Anidulafungin</th>
<th>5FC</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Candida albicans</em></td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><em>C. parapsilosis</em></td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><em>C. tropicalis</em></td>
<td>++</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
</tr>
<tr>
<td><em>C. glabrata</em></td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td><em>C. krusei</em></td>
<td>+</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td><em>Cryptococcus</em> spp.</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>++</td>
<td>-</td>
<td>++</td>
</tr>
<tr>
<td><em>Aspergillus fumigatus</em></td>
<td>++</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><em>A. flavus</em></td>
<td>+-</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><em>A. terreus</em></td>
<td>-</td>
<td>-</td>
<td>++</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td><em>A. nigger</em></td>
<td>++</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Mucorales</td>
<td>++</td>
<td>-</td>
<td>-</td>
<td>++</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><em>Fusarium spp.</em></td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
<h4 id="mdro"><a class="toclink" href="../../../../medicine/antibiotics/#mdro">MDRO</a></h4>
<table>
<thead>
<tr>
<th>抗藥性細菌</th>
<th>可治療藥物（粗體字為首選）</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amp-C β-lactamase GNB</td>
<td>cefepime, <strong>carbapenems</strong>, fluoroquinolones, tigecycline</td>
</tr>
<tr>
<td>ESBL</td>
<td><strong>carbapenems</strong>, (ceftazidime, piperacillin/tazobactam, fluoroquinolone, trimethoprim-sulfamethoxazole, tigecycline, fosfomycin)</td>
</tr>
<tr>
<td>MRSA</td>
<td><strong>vancomycin</strong>, teicoplanin, daptomyxin, linezolid, tigecycline, ceftaroline, (trimethoprim-sulfamethoxazole, clindamycin, doxycycline)</td>
</tr>
<tr>
<td>PsA</td>
<td>pip/tazo, ceftazidime, cefoperazone, cefepime, ceftazidime/avibactam, meropenem, imipenem, doripenem, ciprofloxacin, levofloxacin, aminoglycosides, cefiderocol, aztreonam</td>
</tr>
<tr>
<td>MDRAB</td>
<td>carbapenem, <strong>sulbactam</strong>, colistin, tigecycline, minocycline, cefiderocol</td>
</tr>
<tr>
<td>CRE</td>
<td>ceftazidime/avibactam, aminoglycosides, colistin, tigecycline, minocycline, cefidericol, aztreonam</td>
</tr>
<tr>
<td>VRE</td>
<td><strong>linezolid</strong>, daptomycin, tigecycline, fosfomycin</td>
</tr>
<tr>
<td>PRSP</td>
<td>ceftriaxone, vancomycin, teicoplanin, tigecycline</td>
</tr>
</tbody>
</table>
<h4 id="_9"><a class="toclink" href="../../../../medicine/antibiotics/#_9">特殊細菌</a></h4>
<ul>
<li>Enterococcus: <strong>ampicillin</strong>; cephalosporins沒有效  </li>
<li>Listeria monocytogenes: <strong>ampicillin</strong>; linezolid, trimethoprim-sulfamethoxazole, penicillin, gentamicin  </li>
<li>Clostridioides difficile: metronidazole, vancomycin, fidaxomicin  </li>
<li>Pasteurella multocida: <strong>amoxicillin/clavulanic acid</strong>, penicillin, amoxicillin, cefuroxime, levofloxacin, moxifloxacin, doxycycline, trimethoprim-sulfamethoxazole  </li>
<li>Neisseria gonorrhoeae: <strong>ceftriaxone</strong>  </li>
<li>Neisseria meningitides: <strong>penicillin</strong>; ceftriaxone  </li>
<li>Salmonella spp.: <strong>ceftriaxone</strong>, fluoroquinolone  </li>
<li>Vibrio: tetracyclines, fluoroquinolone, trimethoprim-sulfamethoxazole  </li>
<li>Stenotrophomonas maltophila: <strong>trimethoprim-sulfamethoxazole</strong>; levofloxacin, minocycline, colistin  </li>
<li>Burkholderia pseudomallei: ceftazidime, meropenem, imipenem  </li>
<li>Legionella: azithromycin or quinolone  </li>
<li>Treponema pallidum: penicillin; ceftriaxone, doxycycline  </li>
<li>Mycoplasma pneumoniae: tetracyclines, erythromycin  </li>
<li>Chlamydia spp.: tetracyclines, azithromycin  </li>
<li>Anaerobes: <strong>metronidazole</strong>, amp/sulb, pip/tazo, cephamycin, carbapenems, clindamycin, moxifloxacin, tigecycline  </li>
</ul>
<h4 id="drugs-of-choices"><a class="toclink" href="../../../../medicine/antibiotics/#drugs-of-choices">Drugs of choices</a></h4>
<table>
<thead>
<tr>
<th>ANTIMICROBIAL(S)</th>
<th>INFECTIONS</th>
<th>COMMON PATHOGENS (% SUSCEPTIBLE); RESISTANCE AS NOTED[^a]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penicillin G</td>
<td>梅毒；yaws；鉤端螺旋體病；鏈球菌感染；肺炎鏈球菌感染；放線菌病；口腔和牙周感染；流行性腦膜炎及腦膜炎雙球菌血症；草綠色鏈球菌心內膜炎；梭狀芽孢桿菌性肌壞死；破傷風；鼠咬熱；Pasteurella multocida 感染；丹毒（Erysipelothrix rhusiopathiae）</td>
<td><em>Neisseria meningitidis</em>; viridans streptococci (69%); <em>Streptococcus pneumoniae</em> (97% nonmeningitis; 75% meningitis)</td>
</tr>
<tr>
<td>Ampicillin, amoxicillin</td>
<td>Salmonellosis; 急性中耳炎; <em>Haemophilus influenzae</em> 腦膜炎和會厭炎 ; <strong><em>Listeria monocytogenes</em> 腦膜炎; <em>Enterococcus faecalis</em> UTI</strong></td>
<td><em>Escherichia coli</em> (51%); <em>H. influenzae</em> (70%); <em>Salmonella</em> spp. (85%)</td>
</tr>
<tr>
<td>Nafcillin, oxacillin</td>
<td><strong>MSSA</strong>菌血症和心內膜炎</td>
<td><em>Staphylococcus aureus</em> (70%); coagulase-negative staphylococci (50%)</td>
</tr>
<tr>
<td>Piperacillin-tazobactam</td>
<td>腹腔內感染（兼性腸道革蘭氏陰性桿菌和絕對厭氧菌）；混合菌叢引起的感染（吸入性肺炎、糖尿病足潰瘍）；由 Pseudomonas aeruginosa 引起的感染</td>
<td><em>P. aeruginosa</em> (82%)</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>E. coli UTI；手術預防；MSSA 菌血症和心內膜炎</td>
<td><em>E. coli</em> (82%)</td>
</tr>
<tr>
<td>Cefoxitin, cefotetan</td>
<td>腹腔內感染和骨盆炎性疾病</td>
<td><em>Bacteroides fragilis</em> (60%)[^b]</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>淋病；肺炎鏈球菌腦膜炎；草綠色鏈球菌心內膜炎；沙門氏菌病和傷寒；由非<em>Pseudomonas aeruginosa</em>引起的院內感染</td>
<td><em>S. pneumoniae</em> (91% meningitis; 99% nonmeningitis); <em>E. coli</em> (90%); <em>Klebsiella pneumoniae</em> (88%)</td>
</tr>
<tr>
<td>Ceftazidime, cefepime</td>
<td>由兼性革蘭氏陰性桿菌和 <em>Pseudomonas</em> spp. 引起的院內感染</td>
<td><em>P. aeruginosa</em> (86%)</td>
</tr>
<tr>
<td>Ceftaroline</td>
<td><em>S. pneumoniae</em>, MSSA, <em>H. influenzae, K. pneumoniae, Klebsiella oxytoca, E. coli</em>引起的CAP；由 MSSA, MRSA, <em>Streptococcus pyogenes, Streptococcus agalactiae, E. coli, K. pneumoniae, K. oxytoca</em> 引起的急性細菌性皮膚及皮膚結構感染</td>
<td>大多數對 Ceftaroline 敏感；來自單一希臘醫院的四株 MRSA 分離株對 Ceftaroline 的 MIC &gt;4 μg/mL[^c]；其他個案報告，包括在未曾接觸 ceftaroline 的患者[^d,e]</td>
</tr>
<tr>
<td>Ceftazidime-avibactam, meropenem-vaborbactam</td>
<td>由抗藥性革蘭氏陰性菌（包括 <em>Pseudomonas</em> 和一些厭氧菌）引起的複雜性尿路感染和複雜性腹腔內感染（ceftazidime-avibactam 與 metronidazole 併用）</td>
<td><em>P. aeruginosa</em> (84–97%)[^f]<br><br>MDR Enterobacterales, including carbapenem-resistant Enterobacterales that produce KPCs<br><br>No activity against metallo-β-lactamases (e.g., NDM)</td>
</tr>
<tr>
<td>Imipenem, meropenem</td>
<td>由 <em>Enterobacter</em> spp. 和產生 ESBL 的革蘭氏陰性桿菌引起的腹腔內感染</td>
<td><em>P. aeruginosa</em> (84%); <em>Acinetobacter calcoaceticus-baumannii</em> complex (85%) (meropenem susceptibilities reported)</td>
</tr>
<tr>
<td>Ertapenem</td>
<td>CAP；複雜性尿路感染，包括腎盂腎炎；急性骨盆感染；複雜性腹腔內感染；複雜性皮膚和皮膚結構感染，不包括伴有骨髓炎或由 <em>P. aeruginosa</em> 引起的糖尿病足感染</td>
<td><em>Enterobacter cloacae</em> (90%); <em>K. pneumoniae</em> (98%)</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>對penicillin過敏患者由兼性革蘭氏陰性桿菌和 <em>Pseudomonas</em> 引起的感染</td>
<td><em>P. aeruginosa</em> (69%)</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>由 MRSA 引起的菌血症、心內膜炎和其他侵襲性疾病；肺炎鏈球菌腦膜炎；口服製劑用於 CDAD</td>
<td><em>S. aureus</em> (100%); <em>E. faecalis</em> (96%); <em>E. faecium</em> (34%)</td>
</tr>
<tr>
<td>Daptomycin</td>
<td>VRE 感染；MRSA 菌血症</td>
<td><em>E. faecalis</em> (99.9%)[^i]; <em>E. faecium</em> (99.7%)[^i]; <em>S. aureus</em> (99.9%)[^g]</td>
</tr>
<tr>
<td>Gentamicin, amikacin, streptomycin, tobramycin</td>
<td>與penicillin併用治療葡萄球菌、腸球菌或鏈球菌心內膜炎；與 β-lactam類併用治療革蘭氏陰性菌血症；腎盂腎炎</td>
<td><em>E. coli</em> (gentamicin, 91%); <em>P. aeruginosa</em> (amikacin, 82%; gentamicin, 84%); <em>A. calcoaceticus-baumannii</em> complex (gentamicin, 89%)</td>
</tr>
<tr>
<td>Azithromycin, clarithromycin, erythromycin</td>
<td><em>Legionella, Campylobacter</em>, <em>Mycoplasma</em> 感染；CAP；對penicillin過敏患者的A型鏈球菌咽喉炎；細菌性血管瘤病；<em>Helicobacter pylori</em>；鳥型分枝桿菌感染</td>
<td><em>S. pneumoniae</em> (60%); group A streptococci (82%); <em>H. pylori</em> (75%)j</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>嚴重、侵襲性的A型鏈球菌感染（與 β-lactam合用）；由絕對厭氧菌引起的感染；由敏感的葡萄球菌引起的感染</td>
<td><em>S. aureus</em> (70%)</td>
</tr>
<tr>
<td>Doxycycline, minocycline</td>
<td>慢性支氣管炎的急性細菌性加重；輕度CAP；MRSA皮膚和軟組織感染；<em>Vibrio vulnificus</em> 感染；披衣菌 (doxycycline)；Rickettsia感染（恙蟲病、斑疹傷寒）；penicillin過敏者治療放線菌感染；<strong>鉤端螺旋體感染；梅毒；類鼻疽</strong>；鼻疽；鼠疫；布魯氏菌病（與streptomycin合用）；兔熱病；萊姆病 (doxycycline)；腹股溝肉芽腫<br><br> <strong><em>Stenotrophomonas, Mycobacterium marinum</em></strong>感染 (minocycline)<br><mark>健保給付僅限對CRAB</mark></td>
<td><em>S. pneumoniae</em> (63%); <em>S. aureus</em> (97%)</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>由 <em>S. pneumoniae, H. influenzae</em>, or <em>Legionella pneumophila</em> 引起的CAP；由 <em>E. coli</em>, vancomycin-susceptible <em>E. faecalis, Citrobacter freundii, E. cloacae, K. pneumoniae, K. oxytoca, Bacteroides</em> spp., <em>Clostridium perfringens</em>, and <em>Peptostreptococcus</em> spp.多重抗藥革蘭氏陰性菌和厭氧菌引起的複雜性腹腔內感染；由 <em>E. coli</em>, MRSA, MSSA, <em>S. pyogenes, Streptococcus anginosus, S. agalactiae, B. fragilis</em> 引起的複雜性皮膚和軟組織感染</td>
<td>Mostly susceptible, although case reports of resistance in <em>A. baumannii</em> and <em>K. pneumoniae</em></td>
</tr>
<tr>
<td>TMP-SMX</td>
<td>社區性UTI和社區性MRSA皮膚和軟組織感染</td>
<td><em>E. coli</em> (73%); <em>S. aureus</em> (95%)</td>
</tr>
<tr>
<td>Ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin</td>
<td>CAP (levofloxacin and moxifloxacin); UTI; <em>Pseudomonas</em> infections (ciprofloxacin and levofloxacin)；醫院獲得性革蘭氏陰性腸道感染；細菌性腸胃炎</td>
<td><em>S. pneumoniae</em> (99% levofloxacin); <em>E. coli</em> (79% for ciprofloxacin and levofloxacin); <em>P. aeruginosa</em> (ciprofloxacin, 76%; levofloxacin, 70%); <strong><em>Salmonella</em> spp.</strong> (72% for ciprofloxacin and levofloxacin)</td>
</tr>
<tr>
<td>Rifampin</td>
<td><strong>葡萄球菌異物感染（與其他抗葡萄球菌藥物聯合使用）; <em>Legionella</em> pneumonia</strong>; <em>Mycobacterium tuberculosis</em>; atypical nontuberculous mycobacterial infection</td>
<td><em>S. aureus</em> (99%), although staphylococci rapidly develop resistance with monotherapy</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>絕對厭氧革蘭氏陰性菌（如 Bacteroides spp.）；肺、腦或腹部膿瘍；細菌性陰道炎；CDAD</td>
<td>Mostly susceptible; resistance very rare</td>
</tr>
<tr>
<td>Linezolid, tedizolid</td>
<td>VRE; 由 MSSA 和 MRSA 引起的皮膚及軟組織感染；伴有菌血症的CAP；HAP</td>
<td>Mostly susceptible; resistance occasionally seen in VRE</td>
</tr>
<tr>
<td>Colistin</td>
<td>由對其他所有治療方案耐藥的革蘭氏陰性桿菌引起的感染 (如 <em>P. aeruginosa, Acinetobacter</em> spp., and <em>Stenotrophomonas maltophilia</em>)</td>
<td><em>P. aeruginosa</em> (case reports, outbreaks)</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>大多數革蘭氏陰性桿菌和一些革蘭氏陽性菌引起的UTI；反復性膀胱炎的預防</td>
<td><em>E. coli</em> (95%); <em>E. faecalis</em> (99%)</td>
</tr>
<tr>
<td>Fosfomycin</td>
<td>大多數革蘭氏陰性桿菌和一些革蘭氏陽性菌引起的尿路感染；反復性膀胱炎的預防</td>
<td>被認為是低抗藥性</td>
</tr>
<tr>
<td>Cefiderocol</td>
<td>由多重抗藥革蘭氏陰性菌引起的複雜性尿路感染和/或腎盂腎炎，包括產生ESBL或carbapenemase的細菌以及多重抗藥性<em>Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, Burkholderia cepacia complex</em></td>
<td>初步研究中顯示抗藥機率非常低</td>
</tr>
</tbody>
</table>
<h3 id="_10"><a class="toclink" href="../../../../medicine/antibiotics/#_10">孕婦</a></h3>
<ul>
<li>不建議使用aminoglycosides, tetracyclines  </li>
<li>Metronidazole, trimethoprim-sulfamethoxazole第一孕期禁用  </li>
</ul>
<h3 id="_11"><a class="toclink" href="../../../../medicine/antibiotics/#_11">常見副作用</a></h3>
<h4 id="ampicillinsulbactam"><a class="toclink" href="../../../../medicine/antibiotics/#ampicillinsulbactam">Ampicillin/sulbactam</a></h4>
<ul>
<li>腹瀉  </li>
<li>偽膜性腸炎  </li>
</ul>
<h4 id="piperacillintazobactam"><a class="toclink" href="../../../../medicine/antibiotics/#piperacillintazobactam">Piperacillin/tazobactam</a></h4>
<ul>
<li>腎毒性  </li>
<li>腸道菌群失衡（可能導致偽膜性腸炎）  </li>
<li>血小板減少症  </li>
</ul>
<h4 id="ceftriaxone"><a class="toclink" href="../../../../medicine/antibiotics/#ceftriaxone">Ceftriaxone</a></h4>
<ul>
<li>肝毒性、黃疸  </li>
<li>不可加入含鈣之點滴注射液  </li>
</ul>
<h4 id="cefepime"><a class="toclink" href="../../../../medicine/antibiotics/#cefepime"><strong>Cefepime</strong></a></h4>
<ul>
<li>神經毒性（尤其是在腎功能受損的病人中，可能引起癲癇）  </li>
</ul>
<h4 id="carbapenems_1"><a class="toclink" href="../../../../medicine/antibiotics/#carbapenems_1">Carbapenems</a></h4>
<ul>
<li>神經毒性（特別是在高劑量或腎功能不全時）  </li>
</ul>
<h4 id="aminoglycosides-gentamicin"><a class="toclink" href="../../../../medicine/antibiotics/#aminoglycosides-gentamicin">Aminoglycosides (Gentamicin)</a></h4>
<ul>
<li>腎毒性：preexisting renal impairment, concomitant nephrotoxic medications, advanced age and dehydration  </li>
<li>耳毒性（可能引起聽力損失或平衡障礙）：proportional to the amount of drug given and the duration of treatment; tinnitus or vertigo may be indications of vestibular injury and impending bilateral irreversible damage  </li>
<li>神經肌肉阻礙、呼吸衰竭  </li>
</ul>
<h4 id="sulfamethoxazoletrimethoprim-tmp-smx"><a class="toclink" href="../../../../medicine/antibiotics/#sulfamethoxazoletrimethoprim-tmp-smx">Sulfamethoxazole/Trimethoprim (TMP-SMX)</a></h4>
<ul>
<li>高血鉀  </li>
<li>腎毒性  </li>
<li>肝毒性  </li>
<li>過敏反應  </li>
<li>骨髓抑制（可能引起貧血、白血球減少、血小板減少）  </li>
</ul>
<h4 id="vancomycin"><a class="toclink" href="../../../../medicine/antibiotics/#vancomycin">Vancomycin</a></h4>
<ul>
<li>腎毒性  </li>
<li>耳毒性  </li>
<li>嗜中性球低下、白血球減少、血小板減少  </li>
<li><mark><strong>Red man syndrome</strong></mark>：與vancomycin的劑量有所關聯，特別是發生在劑量較大且快速滴注時。主要是由皮膚、肺、腸胃道、心肌及血管系統中的<strong>肥大細胞</strong>及嗜鹼性白血球釋出<strong>組織胺</strong>所導致的。此現象通常發生在首次的給予劑量，但也可能會發生在任何一個給藥時間。一般常見的典型的症狀為<strong>上半身軀幹</strong>有潮紅、紅疹、蕁麻疹及搔癢之現象，在幾個比較嚴重的案例中曾發現低血壓、胸痛及呼吸窘迫之症狀。  </li>
<li>全身性過敏反應：是一種急性且危及生命的免疫反應，一般發生非常迅速，通常在給藥後之5-30分鐘以內發作。首先病人會對vancomycin敏感而在體內產生vancomycin特異性的IgE（vancomycin-specific IgE）。若對產生過敏之病人重複投予vancomycin會造成敏感性肥大細胞上的IgE接受器產生交叉連結反應，而引起血管活化調節物質的釋出，這些物質例如有組織胺、白三稀素C4（leukotriene C4）、前列腺素（prostaglandin D2）及細胞介質素，例如：腫瘤壞死因子（TNF-a）及interleukin 4, 5, 6, 7, 8及13。因為這些物質之釋出而擴大vancomycin之過敏反應進而產生血管擴張作用引起全身性皮膚紅疹、搔癢、蕁麻疹、支氣管收縮、腸道過度蠕動、低血壓或心律不整。  </li>
</ul>
<h4 id="daptomycin"><a class="toclink" href="../../../../medicine/antibiotics/#daptomycin">Daptomycin</a></h4>
<ul>
<li>肌肉病變（myopathy）  </li>
<li>Drug-induced eosinophilic pneumonia（少見）  </li>
<li>Do not use for primary pneumonia: inactivated by pulmonary surfactant  </li>
</ul>
<h4 id="linezolid"><a class="toclink" href="../../../../medicine/antibiotics/#linezolid">Linezolid</a></h4>
<ul>
<li>肝毒性  </li>
<li>血球低下（使用兩周以上）  </li>
<li>不可與單胺氧化酶抑制劑(monoamine oxidase inhibitor)或selective serotonin re-uptake inhibitor共同使用（serotonin syndrome）  </li>
<li>視神經病變  </li>
<li>乳酸中毒（少見）  </li>
</ul>
<h4 id="clindamycin"><a class="toclink" href="../../../../medicine/antibiotics/#clindamycin">Clindamycin</a></h4>
<ul>
<li>腹瀉  </li>
<li>偽膜性腸炎（由困難梭狀桿菌引起）  </li>
<li>皮疹  </li>
<li>肝毒性  </li>
</ul>
<h4 id="tetracyclines-doxycycline-minocycline"><a class="toclink" href="../../../../medicine/antibiotics/#tetracyclines-doxycycline-minocycline">Tetracyclines (如doxycycline, minocycline)</a></h4>
<ul>
<li>光感受性  </li>
<li>胃腸不適  </li>
<li>骨骼和牙齒發育障礙（特別是在兒童中）  </li>
<li>肝毒性  </li>
<li>併用Warfarin會加強Warfarin抗凝血功能增加出血的風險  </li>
</ul>
<h4 id="fluoroquinolones_1"><a class="toclink" href="../../../../medicine/antibiotics/#fluoroquinolones_1">Fluoroquinolones</a></h4>
<ul>
<li>QTc 延長  </li>
<li>肌腱炎及肌腱斷裂、關節病變（兒童不適合使用，老年人和同時用steroid的人使用fluoroquinolone會增加此副作用之風險）  </li>
<li>血糖異常（高血糖或低血糖）  </li>
<li>與aortic aneurysm or dissection可能有關  </li>
</ul>
<h4 id="macrolides_1"><a class="toclink" href="../../../../medicine/antibiotics/#macrolides_1">Macrolides</a></h4>
<ul>
<li>胃腸道不適（如腹瀉、噁心）  </li>
<li>QTc 延長  </li>
<li>肝毒性  </li>
</ul>
<h4 id="metronidazole"><a class="toclink" href="../../../../medicine/antibiotics/#metronidazole">Metronidazole</a></h4>
<ul>
<li>腸胃不適（如噁心、嘔吐）  </li>
<li>周邊神經病變（長期使用）  </li>
<li>口腔金屬味  </li>
<li>酒精不耐受反應  </li>
</ul>
<h4 id="fluconazole"><a class="toclink" href="../../../../medicine/antibiotics/#fluconazole">Fluconazole</a></h4>
<ul>
<li>QTc 延長  </li>
<li>肝毒性  </li>
</ul>
<h4 id="amphotericin-b"><a class="toclink" href="../../../../medicine/antibiotics/#amphotericin-b">Amphotericin B</a></h4>
<ul>
<li>腎毒性  </li>
<li>低血鉀  </li>
<li>輸注反應：發燒、寒顫、頭痛、心搏過速  </li>
</ul>
<h3 id="_12"><a class="toclink" href="../../../../medicine/antibiotics/#_12">考古題</a></h3>
<h4 id="_13"><a class="toclink" href="../../../../medicine/antibiotics/#_13">專師</a></h4>
<h4 id="_14"><a class="toclink" href="../../../../medicine/antibiotics/#_14">內科醫師</a></h4>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-09 00:00:00">August 9, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="../../../../category/medicine/" class="md-meta__link">medicine</a></li>
        
        
          
          <li class="md-meta__item">
            
              3 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="cns-infection"><a class="toclink" href="../../../../medicine/cns-infection/">CNS Infection</a></h2>
<p>source:: Pocket Medicine, 2022  </p>
<h3 id="_1"><a class="toclink" href="../../../../medicine/cns-infection/#_1">急性細菌性腦膜炎</a></h3>
<h4 id="_2"><a class="toclink" href="../../../../medicine/cns-infection/#_2">定義</a></h4>
<ul>
<li>腦/脊髓周圍組織的發炎  </li>
<li>通常起源於鼻咽部（血行播散）、菌血症或直接接種（手術、鄰近感染、創傷、異物［如腦脊液分流管］）  </li>
</ul>
<hr />
<h5 id="nejm-20113642016"><a class="toclink" href="../../../../medicine/cns-infection/#nejm-20113642016"><strong>細菌性腦膜炎中的微生物學</strong> (<em>NEJM</em> 2011;364:2016)</a></h5>
<table>
<thead>
<tr>
<th>病原體</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Streptococcus pneumoniae</em> (30-60%)</td>
<td>常見於有前驅感染（菌血症、肺炎、心內膜炎）患者<br><br>抗藥性_S. pneumoniae_:<br> - 約40%對PCN抗藥（即使是中度抗藥也很麻煩）<br>- 約10%對第三代頭孢菌素抗藥</td>
</tr>
<tr>
<td><em>Neisseria meningitidis</em> (10-35%)</td>
<td>主要見於年齡小於30歲的患者，常伴有瘀點或紫斑<br><br>在無脾症、補體缺乏、HIV、SCT、未接種疫苗者中風險增加<br><br>建議所有11-18歲的青少年、HIV感染者、無脾症者、C5-9缺乏者接種疫苗</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em> (&lt;5%)</td>
<td>無脾症、補體缺乏、HIV、SCT、未接種疫苗、腦脊液漏、創傷/手術、乳突炎患者中風險增加<br><br>建議所有兒童接種疫苗；發病率顯著降低</td>
</tr>
<tr>
<td><em>Listeria monocytogenes</em> (5-10%)</td>
<td>在免疫抑制（類固醇使用、移植）、老年人、惡性腫瘤、孕婦、肝硬化患者中增加<br>爆發常與受污染的乳製品和生蔬菜有關</td>
</tr>
<tr>
<td>GNBs (1-10%)</td>
<td>在與醫療保健相關的腦膜炎中較常見（如_Escherichia coli_、<em>Klebsiella</em>、<em>Pseudomonas aeruginosa</em>）</td>
</tr>
<tr>
<td><em>Staphylococci</em> (5%)</td>
<td>前驅感染（心內膜炎、菌血症）、CNS手術後、異物（腦脊液分流管、硬膜下幫浦）相關</td>
</tr>
<tr>
<td>混合感染</td>
<td>應懷疑顱旁感染灶或腦脊液漏、CNS手術後感染</td>
</tr>
</tbody>
</table>
<h4 id="lancet-201633916"><a class="toclink" href="../../../../medicine/cns-infection/#lancet-201633916">臨床表現 (Lancet 2016;339:16)</a></h4>
<ul>
<li>頭痛 (84%)、發燒 (74%)、頸部僵硬 (74%)、畏光、GCS &lt;14 (71%)、噁心 (62%)、癲癇發作 (23%)；95%患者有以下4種症狀中的2種：頭痛、發燒、頸部僵硬、意識改變  </li>
<li>老年人和免疫抑制患者的表現可能不典型（如沒有發燒的嗜睡）  </li>
</ul>
<h4 id="cid-20023546-am-j-emerg-med-2013311601"><a class="toclink" href="../../../../medicine/cns-infection/#cid-20023546-am-j-emerg-med-2013311601">體檢 (CID 2002;35:46; Am J Emerg Med 2013;31:1601)</a></h4>
<ul>
<li>頸部僵硬（靈敏度 30%，特異性 68%）、Kernig’s sign（靈敏度 5%，特異性 95%）、Brudzinsk’s sign（靈敏度 5%，特異性 95%）、Jolt’s sign（頭痛隨水平轉動惡化）（靈敏度 64%，特異性 43%）  </li>
<li>± 局部神經病學發現（約30%；偏癱、失語症、視野缺損、顱神經麻痺）  </li>
<li>± 頭頸耳鼻喉發現：鼻竇壓痛、清澈鼻漏（腦脊液漏）  </li>
<li>± 皮膚和關節發現：瘀點疹（<em>N. meningitidis</em>）、生殖器或口腔潰瘍（HSV）、伴隨關節積液的關節炎（<em>N. meningitidis</em>）  </li>
</ul>
<h4 id="_3"><a class="toclink" href="../../../../medicine/cns-infection/#_3">細菌性腦膜炎的順序管理</a></h4>
<ul>
<li>血液培養，開始經驗性抗生素，考慮使用類固醇（見下文）  </li>
<li>如有適應症，進行頭部CT檢查（見下文）  </li>
<li>儘快進行腰椎穿刺（如果沒有禁忌症）；如果在開始抗生素後約4小時內獲得腦脊液培養，結果不太可能會改變  </li>
</ul>
<h4 id="nejm-20173883036"><a class="toclink" href="../../../../medicine/cns-infection/#nejm-20173883036">診斷研究 (NEJM 2017;388:3036)</a></h4>
<ul>
<li>在使用抗生素前進行2次血液培養  </li>
<li>在健康宿主的細菌性腦膜炎中，白血球計數 &gt;10,000 的機率超過90%  </li>
<li>如果有1個以上的高風險因素，如免疫抑制、CNS疾病史、新發癲癇發作、局部神經學發現、乳頭水腫、GCS &lt;15，則需在腰椎穿刺前進行頭部CT以排除腫瘤效應 (CID 2004;39:1267)  </li>
<li>腰椎穿刺並測量前壓 (NEJM 2006;355:e12)  </li>
<li>將腦脊液送檢進行細胞計數和分類、葡萄糖、蛋白質、革蘭氏染色、細菌培養  </li>
<li>根據臨床懷疑進行額外的腦脊液研究：抗酸桿菌染色/培養（或MTb PCR）、隱球菌抗原、真菌培養、VDRL、PCR（HSV、VZV、腸道病毒）、細胞學  </li>
<li>腦脊液革蘭氏染色的靈敏度為30-90%；如果腰椎穿刺在使用抗生素前進行，培養的靈敏度為80-90%，但如果懷疑為細菌性腦膜炎，抗生素應不延遲使用  </li>
<li>2的規則：<strong>腦脊液白血球&gt;2000、葡萄糖&lt;20、蛋白質&gt;200</strong>，對細菌性腦膜炎的特異性超過98%  </li>
<li>如適當抗生素治療48小時後無臨床反應或腦脊液分流，則需重複腰椎穿刺  </li>
<li>次世代定序技術可提高診斷率 (NEJM 2019;380:2327)  </li>
</ul>
<h5 id="_4"><a class="toclink" href="../../../../medicine/cns-infection/#_4">腦膜炎中典型的腦脊液發現</a></h5>
<table>
<thead>
<tr>
<th><strong>類型</strong></th>
<th><strong>外觀</strong></th>
<th><strong>壓力（cm H2O）</strong></th>
<th><strong>WBC/mm³ <em>主導類型</em></strong></th>
<th><strong>Glc（mg/dL）</strong></th>
<th><strong>TP (mg/dL)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>正常</strong></td>
<td>清澈</td>
<td>9-18</td>
<td>0-5 <em>淋巴細胞</em></td>
<td>50-75</td>
<td>15-40</td>
</tr>
<tr>
<td><strong>細菌性</strong></td>
<td>渾濁</td>
<td>18-30</td>
<td>100-10,000 <em>多形核細胞</em></td>
<td>&lt;45</td>
<td>100-1000</td>
</tr>
<tr>
<td><strong>結核性</strong></td>
<td>渾濁</td>
<td>18-30</td>
<td>&lt;500 <em>淋巴細胞</em></td>
<td>&lt;45</td>
<td>100-200</td>
</tr>
<tr>
<td><strong>真菌性</strong></td>
<td>渾濁</td>
<td>18-30</td>
<td>&lt;300 <em>淋巴細胞</em></td>
<td>&lt;45</td>
<td>40-300</td>
</tr>
<tr>
<td><strong>無菌性</strong></td>
<td>清澈</td>
<td>9-18</td>
<td>&lt;300 <em>多形核細胞</em> → <em>淋巴細胞</em></td>
<td>50-100</td>
<td>50-100</td>
</tr>
</tbody>
</table>
<h4 id="lancet-20123801693"><a class="toclink" href="../../../../medicine/cns-infection/#lancet-20123801693">細菌性腦膜炎的經驗性治療 (<em>Lancet</em> 2012;380:1693)</a></h4>
<table>
<thead>
<tr>
<th><strong>50歲以下成人</strong></th>
<th>Ceftriaxone + vancomycin（濃度15-20），考慮靜脈注射acyclovir</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>50歲以上成人</strong></td>
<td>Ceftriaxone + vancomycin + ampicillin，考慮靜脈注射acyclovir</td>
</tr>
<tr>
<td><strong>免疫抑制者</strong></td>
<td>[Cefepime或meropenem] + vancomycin ± ampicillin（如果已使用meropenem，則不需要ampicillin），考慮靜脈注射acyclovir和真菌覆蓋</td>
</tr>
<tr>
<td><strong>醫療相關感染（如手術、腦脊液分流管）</strong></td>
<td>[Cefepime或meropenem或ceftazidime] + vancomycin</td>
</tr>
</tbody>
</table>
<ul>
<li>可能的話，應根據敏感性或當地的抗藥模式使用針對病原體的治療  </li>
<li>確認適當的劑量，因為腦膜炎中通常需要更高的劑量（但可能需要根據腎功能進行調整）  </li>
<li><strong>類固醇</strong>：如果病原體未知，建議在開始抗生素前或與其同時使用dexamethasone靜脈注射10毫克，每6小時一次，連續4天。對於<strong><em>S. pneumoniae</em>和GCS 8-11</strong>的患者有最大的益處（神經殘疾和死亡率降低約50%）。<mark>避免使用於隱球菌感染</mark>（NEJM 2016;374:542）。  </li>
<li>預防性措施：對於<em>N. meningitidis</em>的密切接觸者，使用rifampin（600 mg口服，每日兩次，持續2天）或ciprofloxacin（500 mg口服，一次）或ceftriaxone（250 mg肌肉注射，一次）  </li>
<li>預防措施：在排除<em>N. meningitidis</em>之前，採取飛沫隔離措施  </li>
</ul>
<h3 id="_5"><a class="toclink" href="../../../../medicine/cns-infection/#_5">無菌性腦膜炎</a></h3>
<h4 id="_6"><a class="toclink" href="../../../../medicine/cns-infection/#_6">定義</a></h4>
<ul>
<li>臨床/實驗室證據顯示腦膜發炎，但細菌培養（腦脊液及血液）結果為陰性  </li>
</ul>
<h4 id="neurology-20066675"><a class="toclink" href="../../../../medicine/cns-infection/#neurology-20066675">病因學 (Neurology 2006;66:75)</a></h4>
<ul>
<li>病毒性：腸病毒是最常見的原因（夏季/秋季；皮疹、腸胃道症狀、上呼吸道感染症狀），HIV、HSV、VZV、腮腺炎、淋巴細胞性脈絡腦膜炎病毒（與齧齒動物接觸）、腦炎病毒、腺病毒、小兒麻痹病毒、CMV、EBV、西尼羅河病毒  </li>
<li>局部細菌感染：腦/硬膜外/硬膜下膿瘍，中樞神經系統敗血性血栓靜脈炎  </li>
<li>治療過的細菌性腦膜炎  </li>
<li>其他感染：結核、真菌（隱球菌、球黴菌）、萊姆病、梅毒、鈎端螺旋體病  </li>
<li>腫瘤：顱內腫瘤（或囊腫）、淋巴瘤性或癌性腦膜炎  </li>
<li>藥物引起的腦膜炎：NSAIDs、靜脈注射免疫球蛋白、抗生素（TMP-SMX、penicillin）、抗癲癇藥  </li>
<li>系統性自體免疫疾病：SLE、類肉瘤、貝賽特氏病、乾燥綜合症、類風濕性關節炎  </li>
<li>Mollaret's：反覆性淋巴細胞性腦膜炎，會自己緩解（通常為HSV-2）  </li>
</ul>
<h4 id="_7"><a class="toclink" href="../../../../medicine/cns-infection/#_7">診斷</a></h4>
<ul>
<li>進行腰椎穿刺以進行腦脊液分析：病毒性病因中常見淋巴細胞增多症（見上方腦膜炎中的典型腦脊液發現表格）  </li>
<li>考慮腦脊液細胞學和腦部/脊髓MRI以評估是否有惡性腫瘤  </li>
<li>如果腦脊液檢查無所發現且經驗性治療無改善，在適當情況下考慮進行血清自體免疫及病毒檢測  </li>
</ul>
<h4 id="_8"><a class="toclink" href="../../../../medicine/cns-infection/#_8">經驗性治療</a></h4>
<ul>
<li>懷疑為細菌性腦膜炎：參見上方細菌性腦膜炎的經驗性治療  </li>
<li>懷疑為病毒性腦膜炎：如果懷疑為HSV腦膜腦炎 → 靜脈注射acyclovir  </li>
<li>病因不明：考慮開始經驗性細菌性腦膜炎治療，同時觀察並等待腦脊液檢查結果  </li>
</ul>
<h3 id="nejm-2018379557"><a class="toclink" href="../../../../medicine/cns-infection/#nejm-2018379557">腦炎 (NEJM 2018;379:557)</a></h3>
<h4 id="_9"><a class="toclink" href="../../../../medicine/cns-infection/#_9">定義</a></h4>
<ul>
<li>腦實質發炎，特徵為腦功能受損（意識改變、神經缺損），通常由原發性病毒感染或病毒感染後發炎引起  </li>
</ul>
<h4 id="20-neurology-20066675-cid-200847303"><a class="toclink" href="../../../../medicine/cns-infection/#20-neurology-20066675-cid-200847303">病因學 (特定病因在&lt;20%的病例中找到; Neurology 2006;66:75; CID 2008;47:303)</a></h4>
<ul>
<li><strong>HSV-1</strong>：所有年齡/季節。如果治療後症狀復發，考慮為病毒復發或自體免疫性腦炎，因為數週後自體免疫疾病的發病率很高 (Lancet Neurol 2018;17:760)  </li>
<li>VZV原發性感染或再活化：± 水泡疹；所有年齡（偏向老年人），所有季節  </li>
<li>蟲媒病毒：評估病媒蚊/地理暴露。蚊子：日本腦炎、西尼羅河病毒。  </li>
<li>腸病毒（coxsackie, echo）：上呼吸道感染/腸胃道症狀前驅；夏末/秋初達高峰  </li>
<li>其他感染：CMV、EBV、HIV、JC病毒、麻疹、腮腺炎、狂犬病、腺病毒、流感病毒、萊姆病  </li>
<li>非感染性：自體免疫/副腫瘤（抗NMDAR、抗Hu、抗Ma2、抗CRMP5、抗mGluR5），感染後脫髓鞘（例如，ADEM）  </li>
</ul>
<h4 id="_10"><a class="toclink" href="../../../../medicine/cns-infection/#_10">臨床表現</a></h4>
<ul>
<li>發燒 + 意識狀態改變（輕微至嚴重）、癲癇發作、局部神經缺損、腦膜腦炎中的頭痛  </li>
</ul>
<h4 id="cid-2013571114"><a class="toclink" href="../../../../medicine/cns-infection/#cid-2013571114">診斷研究 (CID 2013;57:1114)</a></h4>
<ul>
<li>腦脊液分析：淋巴細胞增多症；HSV（95% 敏感度和特異度）、VZV的PCR；根據風險因素考慮其他PCR檢查（CMV/EBV、HIV、JC病毒、腺病毒/腸病毒、西尼羅河病毒）  </li>
<li>如果腦脊液檢查無所發現且經驗性HSV/VZV治療無改善，在適當情況下考慮檢測自體免疫病因及血清病毒檢測  </li>
<li>MRI（如果無法進行則使用CT）；HSV：顳葉；西尼羅河病毒和Powassan病毒：丘腦高信號  </li>
<li>EEG排除癲癇；腦炎中的發現非特異性（HSV的顳葉重點）  </li>
</ul>
<h4 id="_11"><a class="toclink" href="../../../../medicine/cns-infection/#_11">治療</a></h4>
<ul>
<li>HSV/VZV：Acyclovir 10 mg/kg 靜脈注射，每8小時一次；考慮經驗性治療，因為機率較高  </li>
</ul>
<p><a href="../../../CNS">Original</a>  </p>
<h3 id="_12"><a class="toclink" href="../../../../medicine/cns-infection/#_12">考古題</a></h3>
<h4 id="_13"><a class="toclink" href="../../../../medicine/cns-infection/#_13">專師</a></h4>
<h4 id="_14"><a class="toclink" href="../../../../medicine/cns-infection/#_14">內科醫師</a></h4>
    
  </div>
</article>
      
        <article class="md-post md-post--excerpt">
  <header class="md-post__header">
    
    <div class="md-post__meta md-meta">
      <ul class="md-meta__list">
        <li class="md-meta__item">
          <time datetime="2024-08-09 00:00:00">August 9, 2024</time></li>
        
          <li class="md-meta__item">
            in
            
              <a href="../../../../category/medicine/" class="md-meta__link">medicine</a></li>
        
        
          
          <li class="md-meta__item">
            
              3 min read
            
          </li>
        
      </ul>
      
    </div>
  </header>
  <div class="md-post__content md-typeset">
    <h2 id="coronavirus-disease-2019-covid-19-sars-cov-2-infection"><a class="toclink" href="../../../../medicine/covid-19/">CORONAVIRUS DISEASE 2019 (COVID-19) / SARS-COV-2 INFECTION</a></h2>
<p>source: Pocket Medicine, 2022; 台灣診治指引  </p>
<h3 id="_1"><a class="toclink" href="../../../../medicine/covid-19/#_1">微生物學與流行病學</a></h3>
<ul>
<li>透過呼吸道顆粒在人與人之間傳播；無症狀與症狀前的傳播可能發生    </li>
<li>潛伏期：最長可達14天，從暴露到症狀出現的中位時間為4-5天  </li>
<li>確診病人發病==<strong>前2天</strong>==即可能具傳染力  </li>
<li>確診病人上呼吸道檢體可持續檢測SARS-CoV-2核酸陽性平均達==<strong>兩週</strong>==以上，且下呼吸道檢體檢出病毒的時間可能更久  </li>
<li>輕症個案在發病==<strong>10日後</strong>==即無法從上呼吸道檢體成功培養出病毒（部分重症個案或免疫不全者可能延長至20日），此時這些個案的病毒量均很低（ Realtime PCR Ct 值高），目前也沒有證據顯示此時這些個案能傳播疾病  </li>
</ul>
<hr />
<h3 id="_2"><a class="toclink" href="../../../../medicine/covid-19/#_2">臨床表現</a></h3>
<ul>
<li>範圍從無症狀到重病，出現症狀的患者中，81%為輕至中度，<strong>14%為重症</strong>（缺氧），<strong>5%為危重</strong>（ARDS、休克、多重器官衰竭）(<em>JAMA</em> 2020:323;13)  </li>
<li>常見症狀：發燒、寒顫、咳嗽、呼吸困難（約三分之一）、肌肉痛、頭痛、噁心、嘔吐、腹瀉、喪失嗅覺/味覺  </li>
<li>Omicron 變異株相較於其他變異株之症狀較輕微，無症狀者的比例也較高  </li>
<li>重症的危險因素：<strong>年齡≥65歲、心血管疾病、糖尿病、中風、肺病、慢性腎病、肥胖</strong>  </li>
<li>兒童感染 SARS-CoV-2 可能出現 multisystem inflammatory syndrome（MIS-C） ，其臨床表現類似川崎症或毒性休克症候群，症狀包括出疹、結膜炎、休克、心肌損傷或冠狀動脈血管瘤等  </li>
<li>白血球總數一般不高或降低，淋巴球減少  </li>
<li>個案病況可能在發病後第二周惡化；一半的患者在發病後8天（範圍：5-13 天）出現呼吸急促，約有三分之一的個案進展為ARDS ，約有二至三成個案需要加護病房治療，特別是有慢性疾病如糖尿病、高血壓、及心血管疾病的患者  </li>
<li>在肺炎住院的患者中，疾病致死率可高達一成  </li>
<li>實驗室檢查淋巴球減少(lymphopenia)合併D-dimer升高與死亡率呈正相關  </li>
<li>部分 SARS-CoV-2 患者在急性期康復後，會有持續性或新出現的症狀，稱為 COVID-19 急性感染後徵候群 (post-COVID condition)，通常在發病三個月後發生，症狀需至少持續兩個月以上，且無法以其他病因解釋。流行病學研究顯示發生率介於一成至二成之間，主要症狀包括疲倦、呼吸困難、認知功能與睡眠障礙、嗅味覺改變等，但各器官系統均可能出現相關症狀，並常會影響患者日常生活功能。  </li>
</ul>
<h3 id="_3"><a class="toclink" href="../../../../medicine/covid-19/#_3">嚴重度分類</a></h3>
<h4 id="_4"><a class="toclink" href="../../../../medicine/covid-19/#_4">輕度：無併發症之輕症</a></h4>
<p>沒有任何併發症的上呼吸道病毒性感染患者  </p>
<h4 id="_5"><a class="toclink" href="../../../../medicine/covid-19/#_5">中度：肺炎</a></h4>
<p>沒有嚴重肺炎徵候的肺炎患者，無氧氣設備輔助（room air）下血氧飽和度&gt;94%  </p>
<h4 id="_6"><a class="toclink" href="../../../../medicine/covid-19/#_6">重度：嚴重肺炎</a></h4>
<p>青少年或成人：發燒或呼吸道感染，合併下列任一項：<br />
- 呼吸速率 &gt; 30 下/分鐘<br />
- 嚴重呼吸窘迫（severe respiratory distress）PaO2/FiO2 &lt;300<br />
- 無氧氣設備輔助（room air）下血氧飽和度≦ 94%<br />
- 或肺浸潤(infiltration) &gt; 50%  </p>
<h4 id="ards"><a class="toclink" href="../../../../medicine/covid-19/#ards">極重度：急性呼吸窘迫症候群（ARDS）</a></h4>
<p>時序：在已知臨床病因之一周內，新發生呼吸道症狀，或原有之呼吸道症狀加劇。<br />
胸部影像（<strong>X</strong> 光、電腦斷層、肺部超音波等） ：雙側肺部斑塊（opacities） ，且無法只以肋膜積水、肺葉塌陷、或結節解釋。<br />
肺水腫原因（<strong>origin of edema</strong>） ：無法完全以心臟衰竭或體液容積過量（fluid overload）解釋之呼吸衰竭，且須客觀之評估證據，以排除靜水性肺水腫（hydrostatic）。  </p>
<p>氧合度（成人）：<br />
* 輕度 ARDS：200mmHg &lt; PaO2/FiO2 ≤300mmHg（合併 PEEP 或 CPAP ≥ 5 cmH2O，或未接受機械式呼吸輔助）。<br />
* 中度 ARDS：100mmHg &lt; PaO2/FiO2 ≤200mmHg（合併 PEEP ≥ 5 cmH2O，或未接受機械式呼吸輔助）。<br />
* 重度 ARDS：PaO2/FiO2 ≤ 100mmHg（合併PEEP ≥ 5 cmH2O，或未接受機械式呼吸輔助）。<br />
* 當無 PaO2 之數值時，SpO2/FiO2 ≤ 315 可認為有 ARDS（即便患者未接受機械式呼吸輔助）。  </p>
<h3 id="_7"><a class="toclink" href="../../../../medicine/covid-19/#_7">診斷</a></h3>
<ul>
<li>鼻咽、下呼吸道或前鼻腔的RT-PCR檢測  </li>
<li>前鼻腔的快速抗原檢測（敏感度低於PCR）  </li>
<li>胸部X光：通常顯示雙側不透明影（特別是外圍），早期可能正常；若診斷不明可考慮CT  </li>
<li>CT變化不具特異性，可能包括 GGO、肺實質化（consolidation）等。雖病程後期出現間質性變化（interstitial change） ，但目前仍無法確定是否會有肺纖維化（fibrosis）之後遺症  </li>
</ul>
<h3 id="_8"><a class="toclink" href="../../../../medicine/covid-19/#_8">治療</a></h3>
<ul>
<li>Nirmatrelvir/ritonavir (Paxlovid)：能阻止病毒蛋白酶（protease）複製，ritonavir是cytochrome P450 3A4 (CYP3A4)的強抑制劑，可減緩nirmatrelvir被肝臟cytochrome P450分解代謝的速度，而增強其效果  </li>
<li>Molnupiravir：藉由其成份的核苷類似物，讓病毒的複製酶在RNA複製時不斷累積突變，導致無法完全複製而自行消失。因有基因突變等考量，不建議使用於孕婦。  </li>
<li>Remdesivir：抑制病毒聚合酶（RNA polymerase）  </li>
<li>Nirmatrelvir/ritonavir (Paxlovid)：能阻止病毒蛋白酶（protease）複製，ritonavir是cytochrome P450 3A4 (CYP3A4)的強抑制劑，可減緩Nirmatrelvir被肝臟cytochrome P450分解代謝的速度，而增強其效果  </li>
<li>Molnupiravir：藉由其成份的核苷類似物，讓病毒的複製酶在RNA複製時產生有缺陷的RNA，因有基因突變等考量，不建議使用於孕婦  </li>
<li>Remdesivir：抑制病毒聚合酶（RNA polymerase）  </li>
</ul>
<p><img alt="treatment" src="../../assets/images/6e358234a9fbbbf988a503a1c478ac37_MD5.jpeg" />  </p>
<ul>
<li>重症風險因子：≧65 歲、氣喘、癌症、糖尿病、慢性腎病、心血管疾病（不含高血壓）、慢性肺疾（間質性肺病、肺栓塞、肺高壓、氣管擴張、慢性阻塞性肺病）、結核病、慢性肝病（肝硬化、非酒精性脂肪性肝炎、酒精性肝病與免疫性肝炎）、失能（注意力不足及過動症、腦性麻痺、先天性缺陷、發展或學習障礙、脊髓損傷）、精神疾病（情緒障礙、思覺失調症）、失智症、吸菸（或已戒菸者）、BMI ≧ 30、懷孕（或產後六周內）、影響免疫功能之疾病（HIV 感染、先天性免疫不全、實體器官或血液幹細胞移植、使用類固醇或其他免疫抑制劑  </li>
<li>不需使用氧氣：若有重症風險因子，發病五天內可服用Paxlovid和Molnupiravir（限用於無法使用其他建議藥物者），或發病七天內可給予瑞德西韋<strong>三天</strong>  </li>
<li>住院且需要輔助氧氣的患者：<mark><strong>dexamethasone</strong></mark> 6mg QD 最多10天 ± 瑞德西韋<strong>五天</strong>（抑制病毒RNA聚合酶）  </li>
<li>住院且插管或使用ECMO的患者：dexamethasone + tocilizumab（抗IL-6）或baricitinib/tofacitinib（JAK inhibitor）  </li>
<li>血栓發生率隨疾病嚴重程度上升。建議視個案臨床嚴重程度與相關檢驗數據(如，D-dimer、fibrinogen 等)，考慮對嚴重肺炎以上程度患者給予預防性劑量抗凝血劑  </li>
<li>若患者無休克證據，則採取保守性的輸液治療  </li>
<li>對嚴重肺炎以上程度之SARS-CoV-2患者，考慮給予經驗性抗生素/抗病毒藥物以治療其他可能的細菌/病毒感染  </li>
</ul>
<h3 id="_9"><a class="toclink" href="../../../../medicine/covid-19/#_9">預防</a></h3>
<ul>
<li>針對刺突蛋白的疫苗非常有效。雖然可能會感染，但病情會輕得多。  </li>
</ul>
<h4 id="ttsvitt"><a class="toclink" href="../../../../medicine/covid-19/#ttsvitt">TTS/VITT</a></h4>
<ul>
<li>The term thrombosis and thrombocytopenia syndrome (TTS) refers to all thrombocytopenia and thrombotic complications after vaccination.   </li>
<li>Based on clinical similarities to “autoimmune” or “spontaneous” heparin-induced thrombocytopenia, Immunoglobulin G (IgG) antibodies cross-reacting with “unbound” platelet factor 4 (PF4) in assays for heparin-induced thrombocytopenia (HIT) were soon identified in a subgroup of patients with TTS, termed vaccine-induced immune thrombotic thrombocytopenia (VITT).  </li>
<li>The term thrombosis and thrombocytopenia syndrome (TTS) refers to all thrombocytopenia and thrombotic complications after vaccination.   </li>
<li>Based on clinical similarities to “autoimmune” or “spontaneous” heparin-induced thrombocytopenia, Immunoglobulin G (IgG) antibodies cross-reacting with “unbound” platelet factor 4 (PF4) in assays for heparin-induced thrombocytopenia (HIT) were soon identified in a subgroup of patients with TTS, termed vaccine-induced immune thrombotic thrombocytopenia (VITT).  </li>
<li>發生率：&lt; 20 cases / million doses  </li>
</ul>
<h5 id="case-definition-criteria"><a class="toclink" href="../../../../medicine/covid-19/#case-definition-criteria">Case definition criteria</a></h5>
<ul>
<li>Onset of symptoms 5-30 days after COVID-19 vaccine (or up to 42 days if isolated DVT/PE)   </li>
<li>Presence of thrombosis   </li>
<li>Thrombocytopenia (platelet count &lt;150 × 10<sup>9</sup>/L)   </li>
<li>D-dimer &gt;4000 μg/mL (FEU)   </li>
<li>Positive anti-PF4 Abs ELISA   </li>
</ul>
<h5 id="definite-vitt"><a class="toclink" href="../../../../medicine/covid-19/#definite-vitt">Definite VITT</a></h5>
<ul>
<li>Meets all 5 criteria   </li>
</ul>
<h5 id="probable"><a class="toclink" href="../../../../medicine/covid-19/#probable">Probable</a></h5>
<ul>
<li>D-dimer &gt;4000 FEU but one criterion not fulfilled (timing, thrombosis, thrombocytopenia, anti-PF4 Abs), or   </li>
<li>D-dimer unknown or 2000-4000 FEU with all other criteria present   </li>
</ul>
<h5 id="possible"><a class="toclink" href="../../../../medicine/covid-19/#possible">Possible</a></h5>
<ul>
<li>D-dimer unknown or 2000-4000 FEU with one other criterion not fulfilled, or   </li>
<li>Two other criteria not fulfilled (timing, thrombosis, thrombocytopenia, anti-PF4 Abs)   </li>
</ul>
<h5 id="unlikely"><a class="toclink" href="../../../../medicine/covid-19/#unlikely">Unlikely</a></h5>
<ul>
<li>Platelet count &lt;150 × 10<sup>9</sup>/L without thrombosis with D-dimer &lt;2000 FEU, or   </li>
<li>Thrombosis with platelet count &gt;150 × 10<sup>9</sup>/L and D-dimer &lt;2000 FEU, regardless of anti-PF4 Ab result, and/or   </li>
</ul>
<h3 id="_10"><a class="toclink" href="../../../../medicine/covid-19/#_10">考古題</a></h3>
<h4 id="_11"><a class="toclink" href="../../../../medicine/covid-19/#_11">專師</a></h4>
<h4 id="_12"><a class="toclink" href="../../../../medicine/covid-19/#_12">內科醫師</a></h4>
<div class="footnote">
<hr />
<ol>
<li id="fn:3">
<p>對Omicron變異株效果不佳&#160;<a class="footnote-backref" href="../../../../medicine/covid-19/#fnref:3" title="Jump back to footnote 1 in the text">&#8617;</a></p>
</li>
</ol>
</div>
    
  </div>
</article>
      
      
        
          



<nav class="md-pagination">
  <a class="md-pagination__link" href="../../">1</a> <a class="md-pagination__link" href="../2/">2</a> <span class="md-pagination__current">3</span> <a class="md-pagination__link" href="../4/">4</a> <a class="md-pagination__link" href="../5/">5</a> <span class="md-pagination__dots">..</span> <a class="md-pagination__link" href="../8/">8</a>
</nav>
        
      
    </div>
  </div>

          
<script>var target=document.getElementById(location.hash.slice(1));target&&target.name&&(target.checked=target.name.startsWith("__tabbed_"))</script>
        </div>
        
      </main>
      
        <footer class="md-footer">
  
    
      
      <nav class="md-footer__inner md-grid" aria-label="Footer" >
        
          
          <a href="../../../../category/writing/" class="md-footer__link md-footer__link--prev" aria-label="Previous: writing">
            <div class="md-footer__button md-icon">
              
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M20 11v2H8l5.5 5.5-1.42 1.42L4.16 12l7.92-7.92L13.5 5.5 8 11h12Z"/></svg>
            </div>
            <div class="md-footer__title">
              <span class="md-footer__direction">
                Previous
              </span>
              <div class="md-ellipsis">
                writing
              </div>
            </div>
          </a>
        
        
          
          <a href="../../../2023/" class="md-footer__link md-footer__link--next" aria-label="Next: 2023">
            <div class="md-footer__title">
              <span class="md-footer__direction">
                Next
              </span>
              <div class="md-ellipsis">
                2023
              </div>
            </div>
            <div class="md-footer__button md-icon">
              
              <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24"><path d="M4 11v2h12l-5.5 5.5 1.42 1.42L19.84 12l-7.92-7.92L10.5 5.5 16 11H4Z"/></svg>
            </div>
          </a>
        
      </nav>
    
  
  <div class="md-footer-meta md-typeset">
    <div class="md-footer-meta__inner md-grid">
      <div class="md-copyright">
  
  
    Made with
    <a href="https://squidfunk.github.io/mkdocs-material/" target="_blank" rel="noopener">
      Material for MkDocs
    </a>
  
</div>
      
    </div>
  </div>
</footer>
      
    </div>
    <div class="md-dialog" data-md-component="dialog">
      <div class="md-dialog__inner md-typeset"></div>
    </div>
    
    
    <script id="__config" type="application/json">{"base": "../../../..", "features": ["navigation.path", "navigation.footer"], "search": "../../../../assets/javascripts/workers/search.b8dbb3d2.min.js", "translations": {"clipboard.copied": "Copied to clipboard", "clipboard.copy": "Copy to clipboard", "search.result.more.one": "1 more on this page", "search.result.more.other": "# more on this page", "search.result.none": "No matching documents", "search.result.one": "1 matching document", "search.result.other": "# matching documents", "search.result.placeholder": "Type to start searching", "search.result.term.missing": "Missing", "select.version": "Select version"}}</script>
    
    
      <script src="../../../../assets/javascripts/bundle.af256bd8.min.js"></script>
      
        <script src="../../../../js/timeago.min.js"></script>
      
        <script src="../../../../js/timeago_mkdocs_material.js"></script>
      
        <script src="../../../../javascripts/mathjax.js"></script>
      
        <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
      
        <script src="https://cdn.jsdelivr.net/gh/ObsidianPublisher/assets@main/dist/javascript.js"></script>
      
    
  </body>
</html>